Envista Holdings Co. (NYSE:NVST) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. boosted its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 22.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,832 shares of the company’s stock after buying an additional 7,000 shares during the period. Daiwa Securities Group Inc.’s holdings in Envista were worth $910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Headinvest LLC acquired a new position in Envista during the 3rd quarter valued at about $28,000. Fifth Third Bancorp increased its position in Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after buying an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in Envista during the 3rd quarter valued at about $47,000. Covestor Ltd increased its position in Envista by 33.9% during the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock valued at $69,000 after buying an additional 624 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Envista by 69.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,516 shares of the company’s stock valued at $126,000 after buying an additional 1,844 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. William Blair downgraded Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. UBS Group assumed coverage on Envista in a research note on Friday, January 5th. They set a “neutral” rating and a $26.00 price target on the stock. SVB Leerink assumed coverage on Envista in a research note on Monday, February 26th. They set an “underperform” rating and a $19.00 price target on the stock. Leerink Partnrs reiterated an “underperform” rating on shares of Envista in a research note on Monday, February 26th. Finally, TheStreet downgraded Envista from a “c” rating to a “d+” rating in a research note on Wednesday, February 7th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Envista presently has an average rating of “Hold” and an average price target of $29.60.

Envista Trading Up 0.3 %

Shares of NVST opened at $20.28 on Thursday. The stock’s 50-day moving average price is $21.05 and its 200-day moving average price is $22.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.90 and a current ratio of 2.23. Envista Holdings Co. has a 52 week low of $18.95 and a 52 week high of $39.09.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). The business had revenue of $645.60 million for the quarter, compared to analysts’ expectations of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 EPS. As a group, equities analysts predict that Envista Holdings Co. will post 1.43 EPS for the current year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.